MX2023003933A - Derivados de acetamido-feniltetrazol y métodos para utilizar los mismos. - Google Patents

Derivados de acetamido-feniltetrazol y métodos para utilizar los mismos.

Info

Publication number
MX2023003933A
MX2023003933A MX2023003933A MX2023003933A MX2023003933A MX 2023003933 A MX2023003933 A MX 2023003933A MX 2023003933 A MX2023003933 A MX 2023003933A MX 2023003933 A MX2023003933 A MX 2023003933A MX 2023003933 A MX2023003933 A MX 2023003933A
Authority
MX
Mexico
Prior art keywords
methods
acetamido
same
phenyltetrazole
phenyltetrazole derivatives
Prior art date
Application number
MX2023003933A
Other languages
English (en)
Spanish (es)
Inventor
Johnson Yiu- Nam LAU
Michael P Smolinski
Sameer Urgaonkar
Ahmed M Said
Abdel Sayed Nader N Nasief
Laura Beth Pitzonka
Murray John Cutler
Original Assignee
Athenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex Inc filed Critical Athenex Inc
Publication of MX2023003933A publication Critical patent/MX2023003933A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
MX2023003933A 2020-10-07 2021-10-07 Derivados de acetamido-feniltetrazol y métodos para utilizar los mismos. MX2023003933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088788P 2020-10-07 2020-10-07
PCT/US2021/053937 WO2022076663A1 (en) 2020-10-07 2021-10-07 Acetamido-phenyltetrazole derivatives and methods of using the same

Publications (1)

Publication Number Publication Date
MX2023003933A true MX2023003933A (es) 2023-07-05

Family

ID=78483546

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003933A MX2023003933A (es) 2020-10-07 2021-10-07 Derivados de acetamido-feniltetrazol y métodos para utilizar los mismos.

Country Status (11)

Country Link
US (1) US11739089B2 (ko)
EP (1) EP4225747A1 (ko)
JP (1) JP2023544615A (ko)
KR (1) KR20230104151A (ko)
CN (1) CN116964044A (ko)
AU (1) AU2021358074A1 (ko)
CA (1) CA3194694A1 (ko)
IL (1) IL301516A (ko)
MX (1) MX2023003933A (ko)
TW (1) TW202233593A (ko)
WO (1) WO2022076663A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN110312130B (zh) * 2019-06-25 2021-10-15 浙江大华技术股份有限公司 基于三角模式的帧间预测、视频编码方法及设备
TW202233593A (zh) 2020-10-07 2022-09-01 美商亞瑟尼克斯公司 乙醯胺基-苯基四唑衍生物及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU4567193A (en) 1992-07-10 1994-01-31 Laboratoires Glaxo S.A. Anilide derivatives
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
KR101466245B1 (ko) 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
KR101986683B1 (ko) 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
WO2015152433A1 (en) 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
TWI715636B (zh) 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
WO2019071092A1 (en) 2017-10-06 2019-04-11 Athenex HK Innovative Limited ORAL TAXANE COMPOSITIONS OF HIGH POWER AND METHODS
TW202233593A (zh) 2020-10-07 2022-09-01 美商亞瑟尼克斯公司 乙醯胺基-苯基四唑衍生物及其使用方法

Also Published As

Publication number Publication date
AU2021358074A1 (en) 2023-04-27
EP4225747A1 (en) 2023-08-16
KR20230104151A (ko) 2023-07-07
US11739089B2 (en) 2023-08-29
IL301516A (en) 2023-05-01
US20220106312A1 (en) 2022-04-07
CN116964044A (zh) 2023-10-27
JP2023544615A (ja) 2023-10-24
TW202233593A (zh) 2022-09-01
WO2022076663A1 (en) 2022-04-14
CA3194694A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2023003933A (es) Derivados de acetamido-feniltetrazol y métodos para utilizar los mismos.
CR20200532A (es) Compuestos de heteroarilo tetracíclicos
JOP20210241A1 (ar) مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان
MX2022012306A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
EA201000830A1 (ru) Производные пиримидина для лечения астмы, хобл, аллергического ринита, аллергического конъюнктивита, атопического дерматита, рака, гепатита в, гепатита с, вич, впч, бактериальных инфекций и дерматоза
TW200621762A (en) Novel compounds
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
EA200700099A1 (ru) Производные пиридина
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
MEP23808A (en) Pyridine[3,4-b]pyrazinones
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
TW200637817A (en) 5-aminoindole derivatives
MX2022009043A (es) Compuestos de sulfonimidamida como moduladores de nlrp3.
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
MX2023003927A (es) Derivados de acetamido-fenilbenzamida y métodos para utilizar los mismos.
CR20210664A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
MX2012007217A (es) Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos.
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
MX2021013135A (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.